Limits...
Neoadjuvant chemotherapy followed by D2 gastrectomy and esophagojejunal Roux-en-Y anastomosis in gastric small cell carcinoma: A case report.

Xin K, Wei J, Wang H, Guan W, Liu B - Oncol Lett (2014)

Bottom Line: A biopsy was performed under an electronic gastroscope and the pathological analysis resulted in the diagnosis of gastric small cell carcinoma (GSCC).The mass had invaded the liver and the pancreas according to an enhanced computed tomography scan, thus current surgical methods were considered to be of high risk and highly challenging.The patient experienced survival without progression in the 8-month follow-up.

View Article: PubMed Central - PubMed

Affiliation: The Comprehensive Cancer Center of Nanjing Drum-Tower Hospital, Clinical College of Nanjing Medical University, Nanjing, Jiangsu 210008, P.R. China.

ABSTRACT
A 60-year-old male was referred to Nanjing Drum-Tower Hospital (Nanjing, Jiangsu, China) due to the presence of gastric carcinoma. A biopsy was performed under an electronic gastroscope and the pathological analysis resulted in the diagnosis of gastric small cell carcinoma (GSCC). The mass had invaded the liver and the pancreas according to an enhanced computed tomography scan, thus current surgical methods were considered to be of high risk and highly challenging. Following four cycles of neoadjuvant chemotherapy with irinotecan (200 mg, days 1, 21, 41 and 61) and oxaliplatin (120 mg, days, 1, 21, 41 and 61) the patient underwent a D2 gastrectomy and an esophagojejunal Roux-en-Y anastomosis, followed by adjuvant chemotherapy. The patient experienced survival without progression in the 8-month follow-up. To the best of our knowledge, this is one of few cases of GSCC treated with the combination of neoadjuvant chemotherapy, surgery and adjuvant chemotherapy.

No MeSH data available.


Related in: MedlinePlus

(A and B) Enhanced computed tomography following two cycles of neoadjuvant chemotherapy revealing that the lesion (arrows) was clearly decreased in size. (C) There is no evident nodule in the liver.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4214484&req=5

f2-ol-08-06-2549: (A and B) Enhanced computed tomography following two cycles of neoadjuvant chemotherapy revealing that the lesion (arrows) was clearly decreased in size. (C) There is no evident nodule in the liver.

Mentions: Collectively, the electronic gastroscopy (EG) and CT findings supported a final diagnosis of metastatic GSCC. Following a multi-disciplinary discussion between the Departments of General Surgery and Radiation Oncology, it was decided that current surgical methods would be of high risk and highly challenging. A plan was developed to start the treatment of the patient using neoadjuvant chemotherapy. Therefore, the patient underwent treatment with irinotecan (200 mg, days 1, 21, 41 and 61) and oxaliplatin (120 mg, days 1, 21, 41 and 61) for a four-cycle period, without an evident adverse reaction. Following two cycles of chemotherapy, the patient achieved a partial response. The CT scan revealed that the lesion had clearly decreased in size (Fig. 2A and B). The enhanced CT scan revealed that there was no evident nodule in the liver (Fig. 2C). Levels of the CA-125 serum tumor marker dropped to within the normal range. Following four cycles, the patient achieved another partial response, and then another EG was performed. There were certain nodular niduses in the gastric body and the fundus of the stomach (Fig. 3A and B). No abnormality was found in the mucosa of the gastric antrum, neither were congestion, edema, ulcers, bleeding or any other symptoms.


Neoadjuvant chemotherapy followed by D2 gastrectomy and esophagojejunal Roux-en-Y anastomosis in gastric small cell carcinoma: A case report.

Xin K, Wei J, Wang H, Guan W, Liu B - Oncol Lett (2014)

(A and B) Enhanced computed tomography following two cycles of neoadjuvant chemotherapy revealing that the lesion (arrows) was clearly decreased in size. (C) There is no evident nodule in the liver.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4214484&req=5

f2-ol-08-06-2549: (A and B) Enhanced computed tomography following two cycles of neoadjuvant chemotherapy revealing that the lesion (arrows) was clearly decreased in size. (C) There is no evident nodule in the liver.
Mentions: Collectively, the electronic gastroscopy (EG) and CT findings supported a final diagnosis of metastatic GSCC. Following a multi-disciplinary discussion between the Departments of General Surgery and Radiation Oncology, it was decided that current surgical methods would be of high risk and highly challenging. A plan was developed to start the treatment of the patient using neoadjuvant chemotherapy. Therefore, the patient underwent treatment with irinotecan (200 mg, days 1, 21, 41 and 61) and oxaliplatin (120 mg, days 1, 21, 41 and 61) for a four-cycle period, without an evident adverse reaction. Following two cycles of chemotherapy, the patient achieved a partial response. The CT scan revealed that the lesion had clearly decreased in size (Fig. 2A and B). The enhanced CT scan revealed that there was no evident nodule in the liver (Fig. 2C). Levels of the CA-125 serum tumor marker dropped to within the normal range. Following four cycles, the patient achieved another partial response, and then another EG was performed. There were certain nodular niduses in the gastric body and the fundus of the stomach (Fig. 3A and B). No abnormality was found in the mucosa of the gastric antrum, neither were congestion, edema, ulcers, bleeding or any other symptoms.

Bottom Line: A biopsy was performed under an electronic gastroscope and the pathological analysis resulted in the diagnosis of gastric small cell carcinoma (GSCC).The mass had invaded the liver and the pancreas according to an enhanced computed tomography scan, thus current surgical methods were considered to be of high risk and highly challenging.The patient experienced survival without progression in the 8-month follow-up.

View Article: PubMed Central - PubMed

Affiliation: The Comprehensive Cancer Center of Nanjing Drum-Tower Hospital, Clinical College of Nanjing Medical University, Nanjing, Jiangsu 210008, P.R. China.

ABSTRACT
A 60-year-old male was referred to Nanjing Drum-Tower Hospital (Nanjing, Jiangsu, China) due to the presence of gastric carcinoma. A biopsy was performed under an electronic gastroscope and the pathological analysis resulted in the diagnosis of gastric small cell carcinoma (GSCC). The mass had invaded the liver and the pancreas according to an enhanced computed tomography scan, thus current surgical methods were considered to be of high risk and highly challenging. Following four cycles of neoadjuvant chemotherapy with irinotecan (200 mg, days 1, 21, 41 and 61) and oxaliplatin (120 mg, days, 1, 21, 41 and 61) the patient underwent a D2 gastrectomy and an esophagojejunal Roux-en-Y anastomosis, followed by adjuvant chemotherapy. The patient experienced survival without progression in the 8-month follow-up. To the best of our knowledge, this is one of few cases of GSCC treated with the combination of neoadjuvant chemotherapy, surgery and adjuvant chemotherapy.

No MeSH data available.


Related in: MedlinePlus